Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) – Pipeline Review, H1 2018’, provides in depth analysis on Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Central Nervous System, Dermatology, Gastrointestinal, Genetic Disorders, Infectious Disease and Musculoskeletal Disorders under development targeting Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98)

– The report reviews Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

– The report assesses Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

4SC AG

AlfaSigma SpA

Chipscreen Biosciences Ltd

Curis Inc

HitGen LTD

IRBM Science Park SpA

Medivir AB

Merck & Co Inc

Syndax Pharmaceuticals Inc

Zhejiang Hisun Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) Overview

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) Companies Involved in Therapeutics Development

4SC AG

AlfaSigma SpA

Chipscreen Biosciences Ltd

Curis Inc

HitGen LTD

IRBM Science Park SpA

Medivir AB

Merck & Co Inc

Syndax Pharmaceuticals Inc

Zhejiang Hisun Pharmaceutical Co Ltd

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) Drug Profiles

4SC-202 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit HDAC-3 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

entinostat Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fimepinostat Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HG-3001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KDAC-0001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

largazole Drug Profile

Product Description

Mechanism Of Action

R&D Progress

remetinostat Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-3595 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit HDAC for Prostate Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tucidinostat Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vorinostat Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) Dormant Products

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC

3.5.1.98) Product Development Milestones

Featured News & Press Releases

Jan 10, 2018: Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer

Dec 01, 2017: Curis Announces Upcoming Presentation at the American Society of Hematology 59th Annual Meeting & Exposition

Nov 11, 2017: Syndax Announces Presentation of ENCORE 601 Data at Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting

Nov 07, 2017: Syndax to Present Data On Entinostat at SITC 32nd Annual Scientific Meeting

Oct 13, 2017: Remetinostat Phase II Data Demonstrate Efficacy on Skin Lesions, Reduction of Itching and High Tolerability in Patients With Early-stage MF-type CTCL

Oct 05, 2017: Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin

Sep 27, 2017: Clinical trial reveals genetic fault that reduces the effectiveness of leukaemia treatment

Jul 11, 2017: Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy

Jun 11, 2017: First patient enrolled in Phase Ib/II study SENSITIZE of 4SC-202 in melanoma

May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting

May 17, 2017: Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) for the Treatment of Advanced Melanoma

May 16, 2017: Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies

Apr 20, 2017: Syndax Announces Entinostat Data to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting

Apr 19, 2017: GNTbm to begin Phase III clinical trial in Taiwan of epigenetic regulator Chidamide for late-stage breast cancer

Apr 11, 2017: New mechanistic insights into 4SC-202’s epigenetic mode of action

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by 4SC AG, H1 2018

Pipeline by AlfaSigma SpA, H1 2018

Pipeline by Chipscreen Biosciences Ltd, H1 2018

Pipeline by Curis Inc, H1 2018

Pipeline by HitGen LTD, H1 2018

Pipeline by IRBM Science Park SpA, H1 2018

Pipeline by Medivir AB, H1 2018

Pipeline by Merck & Co Inc, H1 2018

Pipeline by Syndax Pharmaceuticals Inc, H1 2018

Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports